tirzepatide adolescent obesity trial Very reassuring data from the first big #zepbound (#tirzepatide/#mounjaro) tirzepatide in adolescents Tirzepatide Outperforms

[11] [53] [54] [55] Evidence-based data from the literature are relatively limited, and some experts suggest that long-term phentermine pharmacotherapy for obesity does not induce abuse or psychological dependence (addiction), drug craving, and that abrupt treatment cessation within the normal prescription dose range does not induce amphetamine-like withdrawal

Moreover, the AHI markedly decreased, accompanied by improvements in daytime sleepiness and sleep architecture normalization

This aligns with the serotonin-enhancing effects of GLP-1 receptor agonists, as increased serotonergic activity is the primary mechanism behind SSRI-related anorgasmia as well

This article focuses on the five FDA-approved versions of tirzepatide and semaglutide

In the SURMOUNT-1 phase-3 trial, tirzepatide produced dose-dependent weight loss reaching about ~21% of total body weight at the 15 mg dose, substantially more than placebo, with gastrointestinal symptoms the most common adverse events [6] [7]

For someone from Connecticut weighing 250 pounds, this could translate to a loss of 37 to 50 pounds without the need for extreme lifestyle alterations